The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.
 
Jamie E. Chaft
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Suzanne Eleanor Dahlberg
Patents, Royalties, Other Intellectual Property - Patent pending for a statistical model assessing tumor growth (Inst)
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Samsung Bioepis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - ArQule (Inst); BerGenBio (Inst); ImClone Systems (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
Travel, Accommodations, Expenses - ArQule; Bristol-Myers Squibb; Lilly; Lilly
 
Geoffrey R. Oxnard
Honoraria - AstraZeneca; Chugai Pharma
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Inivata; Sysmex; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Shakun M. Malik
No Relationships to Disclose
 
Charles B. Simone
No Relationships to Disclose
 
Martin J. Edelman
Stock and Other Ownership Interests - Biomarker Strategies
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Endocyte (Inst); Genentech/Roche (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - ARIAD; Hospira; Lilly
Other Relationship - AstraZeneca/MedImmune; Boehringer Ingelheim; Lilly; Synta
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Genentech; Medivation; Novartis; Oncomed; Synta
Research Funding - AstraZeneca (Inst)
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer